Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 42,800 shares, a drop of 21.6% from the March 15th total of 54,600 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily volume of 413,000 shares, the short-interest ratio is presently 0.1 days.

Alterity Therapeutics Stock Performance

ATHE stock opened at $3.50 on Monday. The firm’s 50-day moving average is $3.61 and its two-hundred day moving average is $2.75. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $5.87.

Hedge Funds Weigh In On Alterity Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATHE. HB Wealth Management LLC boosted its stake in Alterity Therapeutics by 34.1% during the fourth quarter. HB Wealth Management LLC now owns 31,883 shares of the company’s stock valued at $110,000 after buying an additional 8,100 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Alterity Therapeutics in the 4th quarter worth approximately $29,000. Finally, Point72 Asset Management L.P. acquired a new stake in Alterity Therapeutics during the fourth quarter valued at approximately $108,000. 2.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ATHE has been the subject of several recent research reports. Benchmark lowered shares of Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research note on Monday, February 3rd. Maxim Group boosted their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.